C1QB Antibody

What is C1QB and what is its role in the complement system?

C1QB (complement component 1, q subcomponent, B chain) is a major constituent of the human complement subcomponent C1q. C1q is composed of 18 polypeptide chains: six A-chains, six B-chains, and six C-chains. Each chain contains a collagen-like region located near the N-terminus and a C-terminal globular region .

The C1q molecule associates with the proenzymes C1r and C1s to form C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca²⁺-dependent C1r₂C1s₂ proenzyme complex, and efficient activation of C1 occurs when the globular heads of C1q interact with the Fc regions of IgG or IgM antibodies in immune complexes .

Functionally, C1q plays a crucial role in:

• Initiating the classical complement pathway

• Immune complex clearance

• Modulating inflammatory responses

• Facilitating phagocytosis

C1q deficiency has been clinically associated with autoimmune conditions such as lupus erythematosus and glomerulonephritis .

The C1QB protein has:

• Calculated molecular weight: 27 kDa (based on 253 amino acids)

• Observed molecular weight: 30 kDa in Western blot applications

This small discrepancy between calculated and observed molecular weights (27 kDa vs. 30 kDa) is important to consider when validating antibody specificity. The difference may be attributed to post-translational modifications, particularly:

• Methylation (at K77, K88, K92)

• Phosphorylation (at S125, T127)

When selecting a C1QB antibody, researchers should verify that the antibody can recognize potential post-translational modifications if these are relevant to their research question. Antibody datasheets typically include Western blot images showing the detected band size, which should be consulted prior to purchase.

How can C1QB antibody specificity be validated in experimental systems?

A thorough validation strategy for C1QB antibodies should include:

• Positive and negative control tissues/cells:

  • Human plasma has been validated as a positive control for Western blot

  • Human stomach and kidney tissues are recommended for IHC controls

• Antibody titration experiments:

  • Test multiple dilutions within the recommended range (e.g., 1:500, 1:1000, 1:2000 for WB)

  • Determine optimal signal-to-noise ratio for your specific application

• Knockout/knockdown validation:

  • C1QB knockout or siRNA knockdown cells provide the gold standard for antibody specificity

  • Compare signal between treated and untreated samples

• Antigen competition assay:

  • Pre-incubate antibody with purified C1QB protein or immunizing peptide

  • Observe elimination of specific signal

• Multiple antibody approach:

  • Compare results using antibodies targeting different epitopes of C1QB

  • Consistent results across different antibodies increase confidence in specificity

For researchers studying human samples, several validated monoclonal and polyclonal antibodies are available with specified immunogens that can be compared for their recognition properties .

What are recent findings regarding C1QB expression in disease states?

Recent studies have revealed important correlations between C1QB expression and various pathological conditions:

Cervical Cancer:
A 2022 study demonstrated that C1QB protein expression was significantly higher in cervical cancer samples compared to benign cervical tissue, LSIL (low-grade squamous intraepithelial lesions), and HSIL (high-grade squamous intraepithelial lesions) (p < 0.05). C1QB expression was associated with:

• Depth of tumor infiltration

• Lymphovascular invasion

• Perineural invasion

Additionally, C1QB protein expression positively correlated with P16 and Ki-67 expression in cervical cancer samples (p < 0.05) .

Kidney Transplantation:
In ABO-incompatible kidney transplantation, C1q binding ability was identified as a potential predictor for acute antibody-mediated rejection (ABMR). Research showed that C1q-IgG binding ability was significantly higher in the ABMR group compared to the non-ABMR group (C1q-IgG: 9.04% vs. 5.93%, p = 0.049) .

Additional Associated Conditions:
C1QB has also been implicated in:

• Schizophrenia (through gene polymorphism association)

• Neurodegenerative conditions (including Alzheimer's)

• Potentially cognitive impairment in Parkinson's disease

These findings suggest that C1QB antibodies are valuable tools for investigating the role of complement activation in a variety of disease contexts.

How can researchers quantify C1QB binding ability in serum samples?

For quantifying C1QB binding ability, especially in transplantation research, the following methodology has been validated:

C1q Binding Assay Protocol:

• Sample preparation:

  • To degrade IgM antibodies: Incubate heat-inactivated patient serum with 5 mM dithiothreitol (DTT) at 37°C for 30 minutes

  • For measuring total binding: Use non-DTT treated serum

• Cell preparation and incubation:

  • Incubate 30 μL of 1 × 10⁷/mL DMS-treated RBC with 15 μL of patient serum (DTT treated or non-treated) for 20 minutes at room temperature

  • Wash three times with 0.1% BSA in PBS

• C1q binding:

  • Incubate RBCs with 5 μL of complement component C1q from human serum in PBS at room temperature for 20 minutes

  • Add 50 μL of ×20 diluted FITC-labeled anti-human C1q antibody

  • Incubate at room temperature for 20 minutes

  • Wash twice with 0.1% BSA in PBS

• Flow cytometry analysis:

  • Measure using flow cytometry (e.g., FACS Canto II)

  • Use RBCs reacted with C1q and secondary antibody as negative controls

  • Draw threshold lines at 3% C1q binding ability of the AB blood type serum

  • Compare in terms of positivity rate (%)

This assay can distinguish between C1q-IgG binding (using DTT-treated serum) and C1q-IgG+IgM binding (using non-treated serum), providing insights into the specific antibody classes mediating complement activation.

What protocols yield optimal results for C1QB antibody-based Western blotting?

Based on the validated protocols from antibody manufacturers, the following recommendations can optimize Western blot results:

Sample Preparation:

• Human plasma is the most validated sample type

• Lysate preparation should include protease inhibitors to prevent degradation

• Load 10-20 μg of total protein per lane

Antibody Dilutions and Incubations:

• Primary antibody: 1:500-1:2000 dilution

• Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG at 1:2000 dilution

• For higher signal-to-noise ratio: consider overnight incubation at 4°C

Optimization Steps:

• Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Use freshly prepared antibody dilutions

• Consider adding 0.02% sodium azide to antibody solutions for longer storage

• Include a positive control (human plasma) in each experiment

Visualization Techniques:

• Enhanced chemiluminescence (ECL) detection is commonly used

• Expected band size: 27-30 kDa

Troubleshooting Tips:

• Multiple bands: May indicate protein degradation or post-translational modifications

• No signal: Check protein transfer efficiency and primary antibody reactivity

• High background: Increase washing steps or reduce antibody concentration

What are the optimal conditions for immunohistochemical detection of C1QB?

For successful IHC detection of C1QB, consider the following validated parameters:

Tissue Preparation:

• FFPE (formalin-fixed paraffin-embedded) sections are commonly used

• Human kidney, stomach, and brain tissues have been validated

Antigen Retrieval Methods:

• Heat-mediated antigen retrieval is essential

• Recommended buffers:

  • TE buffer pH 9.0

  • 10mM Tris with 1mM EDTA, pH 9.0 (heat at 95°C for 45 min, then cool at RT for 20 minutes)

  • Alternatively, citrate buffer pH 6.0

Antibody Dilutions:

• Primary antibody: 1:200-1:800 dilution range

• For monoclonal antibodies: incubate for 30 minutes at room temperature

• For polyclonal antibodies: incubate overnight at 4°C

Detection Systems:

• HRP-polymer based detection systems offer high sensitivity

• DAB (3,3'-diaminobenzidine) is commonly used as chromogen

Scoring Methods:
When evaluating IHC results, a semi-quantitative scoring system can be applied:

• Positive cell percentage: 0-5% (0 points), 6-25% (1 point), 26-50% (2 points), 51-75% (3 points), >75% (4 points)

• Staining intensity: No staining (0 points), weak (1 point), moderate (2 points), strong (3 points)

• Final score: Multiply intensity score by positive cell score

How can researchers troubleshoot non-specific binding with C1QB antibodies?

Non-specific binding is a common challenge when working with antibodies. For C1QB antibodies specifically, consider these troubleshooting approaches:

For Western Blot Applications:

• Increase blocking stringency:

  • Use 5% BSA instead of milk for blocking

  • Add 0.1-0.3% Tween-20 to washing buffers

• Optimize antibody concentration:

  • Test serial dilutions (e.g., 1:500, 1:1000, 1:2000)

  • Reduce primary antibody concentration if background is high

• Modify incubation conditions:

  • Shorter incubation times at room temperature

  • Longer incubation times at 4°C to enhance specificity

For Immunohistochemistry Applications:

• Antigen retrieval optimization:

  • Compare different antigen retrieval buffers (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Adjust retrieval time and temperature

• Block endogenous enzymes:

  • Use hydrogen peroxide to block endogenous peroxidase

  • For immunofluorescence, consider quenching autofluorescence

• Secondary antibody considerations:

  • Pre-adsorb secondary antibodies against tissue components

  • Use secondary antibodies specifically adsorbed against other species

General Approaches:

• Include isotype controls for monoclonal antibodies

• Use tissues from C1QB-deficient models as negative controls

• For competitive inhibition tests, pre-incubate the antibody with the immunizing peptide

• Consider using antibodies that target different epitopes of C1QB

What are the considerations for using C1QB antibodies in multiplex immunofluorescence studies?

Multiplex immunofluorescence allows simultaneous detection of multiple targets in the same sample. When incorporating C1QB antibodies in multiplex studies:

Antibody Selection:

• Compatible host species:

  • Choose primary antibodies raised in different host species

  • If using multiple rabbit antibodies, consider directly conjugated versions

• Fluorophore selection:

  • Available conjugates for C1QB antibodies include:

    • CF®405S (Ex/Em: 404/431 nm)

    • CF®488A (Ex/Em: 490/515 nm)

    • CF®568 (Ex/Em: 562/583 nm)

    • PerCP

  • Avoid blue fluorescent dyes (CF®405S) for low abundance targets due to lower fluorescence and higher background

Protocol Considerations:

• Sequential vs. simultaneous staining:

  • Sequential approach: Perform complete staining with first antibody, then proceed to next

  • Simultaneous approach: Apply all primary antibodies together

• Tyramide signal amplification (TSA):

  • Consider for low abundance targets

  • Allows use of antibodies from same host species

• Controls for spectral overlap:

  • Single-stained controls for each fluorophore

  • Unstained controls for autofluorescence

Data Analysis:

• Use spectral unmixing software to separate overlapping fluorescence signals

• For quantitative analysis, establish thresholds based on negative controls

• Consider automated cell segmentation and quantification software

Validated Combinations:
While specific combinations for C1QB have not been directly addressed in the search results, C1QB antibodies could potentially be combined with P16 and Ki-67 antibodies for cervical cancer studies based on their reported correlation .